https://www.selleckchem.com/pr....oducts/gw-441756.htm
The optimal antithrombotic regimen after transcatheter aortic valve replacement remains unclear. In this randomized open-label study, low-risk patients undergoing transfemoral transcatheter aortic valve replacement at 7 centers in the United States were randomized 11 to low-dose aspirin or warfarin plus low-dose aspirin for 30 days. Patients who could not be randomized were enrolled in a separate registry. #link# Computed tomography or transesophageal echocardiography was performed at 30 days. The primary effectiveness end point was a
Like
Comment
Share
